Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.
| Revenue (TTM) | $7.60B |
| Gross Profit (TTM) | $2.90B |
| EBITDA | $1.74B |
| Operating Margin | 21.10% |
| Return on Equity | 7.33% |
| Return on Assets | 4.46% |
| Revenue/Share (TTM) | $5.58 |
| Book Value | $4.78 |
| Price-to-Book | 0.90 |
| Price-to-Sales (TTM) | 0.76 |
| EV/Revenue | 2.005 |
| EV/EBITDA | 9.28 |
| Quarterly Earnings Growth (YoY) | 32.90% |
| Quarterly Revenue Growth (YoY) | 9.40% |
| Shares Outstanding | $258.22M |
| Float | $836.45M |
| % Insiders | 0.00% |
| % Institutions | 57.30% |
Volatility is currently expanding
Grifols remains a speculative 'BUY' with a €20/share price target, offering over 20% annual upside if growth continues. GIKLY has delivered strong 3Q26 results: revenue above €2B quarterly, EBITDA up 10%, net profit up 28%, and leverage now below 4x. Strategic expansion into Egypt is expected to diversify plasma sourcing, reduce costs, and support margin improvement through geographic diversification.
Grifols NASDAQ: GRFS reported third-quarter 2026 results marked by revenue growth, expanding profitability, stronger free cash flow and lower leverage, while management reiterated its full-year financial targets despite continued weakness in China's albumin market.
Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks presents investors with the better value opportunity right now?
Spanish drugmaker Grifols said Health Canada's decision to suspend its license to collect plasma at its Taylor Avenue facility in Winnipeg had no impact on operations.
Grifols is shifting to regional plasma sourcing, aiming for durable cash generation over headline catalysts like a U.S. listing or refinancing. I see improved cash flow as contingent on better sourcing economics, higher network productivity, and incremental plasma protein revenues, not just revenue growth. Despite a 30%+ EV/EBITDA discount to peers, GRFS's value hinges on operational improvements and cash conversion, not simply low multiples.
Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the completion of the clinical portion of SPARTA (Study of ProlAstin-C Randomized Therapy with Alpha-1 augmentation; NCT01983241), its phase 3 outcomes study evaluating the clinical efficacy and safety of two dose regimens of Prolastin®-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema associated with alpha-1 antitrypsin deficiency (AATD), also known as alpha-1.
Grifols NASDAQ: GRFS said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, improving free cash flow and progress in its plasma-sourcing strategy.
BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature immunoglobulin therapeutics, GAMUNEX®-C, an intravenous immunoglobulin (IVIg), and XEMBIFY®, its subcutaneous immunoglobulin (SCIg).
First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GRFS and any ticker you trade — then tracks every position and per-strategy win rate.
